Screening for gastric cancer: Does it make sense?

R. M. Genta

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Gastric cancer remains the second most frequent and lethal malignancy worldwide, with a wide range of incidence rates in different populations. Reducing its incidence is a priority in many high-risk countries, and screening programmes are often advocated as an option. An effective screening programme should have the following characteristics: (i) the disease should be common in the population, otherwise the individual benefit will not offset the risk, cost and inconvenience of screening of the rest of the population; (ii) the diagnostic test(s) used should be safe, simple, inexpensive and reliable; and (iii) effective treatment should be available. With respect to gastric cancer, these conditions are not fulfilled completely in any population and therefore population-based screening does not appear to be a viable approach to the prevention of this neoplasia. In contrast, gastroscopic screening in selected high-risk subjects would seem appropriate. A more effective strategy, particularly in high-incidence populations, could be the widespread screening and treatment for Helicobacter pylori infection. This could result in the virtually complete elimination of chronic gastritis and its associated conditions, including most peptic ulcers, primary gastric B-cell lymphomas and a major portion of gastric epithelial tumours.

Original languageEnglish (US)
Pages (from-to)42-47
Number of pages6
JournalAlimentary Pharmacology and Therapeutics
Volume20
Issue numberSUPPL.2
DOIs
StatePublished - Jul 2004

Fingerprint

Stomach Neoplasms
Population
Incidence
Stomach
Neoplasms
Helicobacter Infections
B-Cell Lymphoma
Gastritis
Peptic Ulcer
Routine Diagnostic Tests
Helicobacter pylori
Costs and Cost Analysis

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Screening for gastric cancer : Does it make sense? / Genta, R. M.

In: Alimentary Pharmacology and Therapeutics, Vol. 20, No. SUPPL.2, 07.2004, p. 42-47.

Research output: Contribution to journalArticle

Genta, R. M. / Screening for gastric cancer : Does it make sense?. In: Alimentary Pharmacology and Therapeutics. 2004 ; Vol. 20, No. SUPPL.2. pp. 42-47.
@article{2d3e0e1e96bf4d989057d6d65d073e1b,
title = "Screening for gastric cancer: Does it make sense?",
abstract = "Gastric cancer remains the second most frequent and lethal malignancy worldwide, with a wide range of incidence rates in different populations. Reducing its incidence is a priority in many high-risk countries, and screening programmes are often advocated as an option. An effective screening programme should have the following characteristics: (i) the disease should be common in the population, otherwise the individual benefit will not offset the risk, cost and inconvenience of screening of the rest of the population; (ii) the diagnostic test(s) used should be safe, simple, inexpensive and reliable; and (iii) effective treatment should be available. With respect to gastric cancer, these conditions are not fulfilled completely in any population and therefore population-based screening does not appear to be a viable approach to the prevention of this neoplasia. In contrast, gastroscopic screening in selected high-risk subjects would seem appropriate. A more effective strategy, particularly in high-incidence populations, could be the widespread screening and treatment for Helicobacter pylori infection. This could result in the virtually complete elimination of chronic gastritis and its associated conditions, including most peptic ulcers, primary gastric B-cell lymphomas and a major portion of gastric epithelial tumours.",
author = "Genta, {R. M.}",
year = "2004",
month = "7",
doi = "10.1111/j.1365-2036.2004.02039.x",
language = "English (US)",
volume = "20",
pages = "42--47",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "SUPPL.2",

}

TY - JOUR

T1 - Screening for gastric cancer

T2 - Does it make sense?

AU - Genta, R. M.

PY - 2004/7

Y1 - 2004/7

N2 - Gastric cancer remains the second most frequent and lethal malignancy worldwide, with a wide range of incidence rates in different populations. Reducing its incidence is a priority in many high-risk countries, and screening programmes are often advocated as an option. An effective screening programme should have the following characteristics: (i) the disease should be common in the population, otherwise the individual benefit will not offset the risk, cost and inconvenience of screening of the rest of the population; (ii) the diagnostic test(s) used should be safe, simple, inexpensive and reliable; and (iii) effective treatment should be available. With respect to gastric cancer, these conditions are not fulfilled completely in any population and therefore population-based screening does not appear to be a viable approach to the prevention of this neoplasia. In contrast, gastroscopic screening in selected high-risk subjects would seem appropriate. A more effective strategy, particularly in high-incidence populations, could be the widespread screening and treatment for Helicobacter pylori infection. This could result in the virtually complete elimination of chronic gastritis and its associated conditions, including most peptic ulcers, primary gastric B-cell lymphomas and a major portion of gastric epithelial tumours.

AB - Gastric cancer remains the second most frequent and lethal malignancy worldwide, with a wide range of incidence rates in different populations. Reducing its incidence is a priority in many high-risk countries, and screening programmes are often advocated as an option. An effective screening programme should have the following characteristics: (i) the disease should be common in the population, otherwise the individual benefit will not offset the risk, cost and inconvenience of screening of the rest of the population; (ii) the diagnostic test(s) used should be safe, simple, inexpensive and reliable; and (iii) effective treatment should be available. With respect to gastric cancer, these conditions are not fulfilled completely in any population and therefore population-based screening does not appear to be a viable approach to the prevention of this neoplasia. In contrast, gastroscopic screening in selected high-risk subjects would seem appropriate. A more effective strategy, particularly in high-incidence populations, could be the widespread screening and treatment for Helicobacter pylori infection. This could result in the virtually complete elimination of chronic gastritis and its associated conditions, including most peptic ulcers, primary gastric B-cell lymphomas and a major portion of gastric epithelial tumours.

UR - http://www.scopus.com/inward/record.url?scp=4544268864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544268864&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2036.2004.02039.x

DO - 10.1111/j.1365-2036.2004.02039.x

M3 - Article

C2 - 15335412

AN - SCOPUS:4544268864

VL - 20

SP - 42

EP - 47

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - SUPPL.2

ER -